Top Markets
Coin of the day
Neovacs S.A. Neovacs S.A.

Neovacs S.A.

ALNEV
株式のランク #21228
Neovacs S.A., a biotechnology company, focuses on the development of... Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
株価
$0.00047446
時価総額
$82.80
変化(1日)
0.00%
変化(1年)
-98.16%
FR
取引 Neovacs S.A. (ALNEV)

カテゴリー

Neovacs S.A.(ALNEV)のP/S比率
April 2026 時点のP/S比率 TTM: 0.00
Neovacs S.A. の最新の財務報告および株価によると、現在のP/S比率(TTM)は 0.00 です。2023 年末時点でのP/S比率は 1.32K でした。
Neovacs S.A. の P/S 比率の履歴(2007 ~ 2026)
各年末時点のP/S比率
P/S比率 変化
2026 (TTM) 0.00 -100.00%
2024 485.89 -63.15%
2023 1.32K 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
2011 0.00 0.00%
2010 0.00 0.00%
2009 0.00 0.00%
2008 0.00 0.00%
2007 0.00 0.00%
同業他社のP/S比率
企業 P/S比率 P/S比率の差
3.54 707,620.00%
DK
9.38 1,874,940.00%
US
5.47 1,094,520.00%
US
6.65 1,330,780.00%
BE
15.23 3,045,540.00%
NL